Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3,...
Read More Details
Finally We wish PressBee provided you with enough information of ( POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS )
Also on site :
- Evacuations ordered after brush fire breaks out in Laguna Beach
- Deal signed for $500m Chaka Housing Project in Addis Ababa
- General YouTube: Germany’s newest military chief is a warlord of his own Ukraine-cheering fantasyland